An observational study in COPD (Chronic Obstructive Pulmonary Disease), sponsored by Chiesi Farmaceutica Ltda.. Recruiting at 1 site in Brazil. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Chiesi Farmaceutica Ltda. (part of Chiesi Farmaceutici S.p.A.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..
Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2026, is one of 9 observational ones, and was the 68th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:
Chiesi Hungary Ltd. · Sites in Hungary
Ages 18+
Chiesi SAS · Sites in France
Ages 40+
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom
Ages 40+
Chiesi UK
Ages 55–75
By country, each count listing its studies:
Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 19 · Phase 3 16 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 396 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 65 across the 59 interventional studies, 661 across the 9 observational. Of the 62 that completed or were terminated, 7 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Chiesi Farmaceutica Ltda., one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
This is the only study on the registry with Chiesi Farmaceutica Ltda. as lead sponsor.
2 of the studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05652439Chiesi Farmaceutici S.p.A.PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI) | 2027-03 |
| NCT07406048Chiesi Farmaceutica Ltda.Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, retrospective-prospective, cohort study aims to evaluate the effectiveness and safety of Extra-fine Beclometasone Diproprionate/Formoterol Fumarate/Glycopyrronium Bromide (EF-BDP/FF/GB) therapy in adults with severe or very severe COPD in Brazil. Around 400 patients will be enrolled across approximately 15 sites. Eligible patients must have started treatment on the day of enrollment or up to three months before enrollment. Data will be collected both retrospectively and prospectively, with baseline information covering up to 12 months before treatment initiation. All assessments will occur during routine medical visits, with follow-up expected at approximately 3 ± 1 month and 6 months ± 2 months. The medication Trimbow® will not be provided as part of the study and must be prescribed and used according to the institution's standard clinical practice, regardless of participation in the study.
Brazilian patients aged ≥ 40 years old, diagnosed with severe and very severe COPD and with a CAT total score ≥ 10 at baseline, under treatment or who will initiate BDP/FF/GB treatment without previous use of single- inhaler triple therapy. Inclusion and exclusion criteria are listed above.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Patient known to be participating in any interventional study during the study period and in the 3 months prior to BDP/FF/GB initiation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients with COPD treated with triple combination Beclometasone Diproprionate/Formoterol Fumarate/Glycopyrronium Bromide (BDP/FF/GB) as per local clinical practice
Drug: BDP/FF/GB (100ug/6ug/12.5ug)
Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium bromide(GB)
Also known as: Trimbow
Assessment of the CAT (COPD assessment test) total score vs baseline at month 6
The test has a score of 0 (minimum) - 40 (maximum); a lower score means a better outcome, and a higher score means a worse outcome.
Time frame: Baseline and 6 months (±2 months)
Assessment of the CAT (COPD assessment test) total score vs baseline at month 3
Time frame: Baseline and 3 months (±1)
Change of Forced Expiratory Volume in one second assessed via spirometry
Absolute value and percent of predicted normal of the following parameter: Forced Expiratory Volume in one second \[FEV1 (L), mean ± SD (standard deviation)\]; Percent predict FEV1 \[FEV1 (% pred), mean ± SD\]
Time frame: Baseline and 6 months (±2)
Change of Forced Vital Capacity assessed via spirometry
Absolute value of the following parameter: Forced Vital Capacity \[FVC (L), mean ± SD\]
Time frame: Baseline and 6 months (±2)
Change of FEV1/FVC ratio assessed via spirometry
Absolute value of the following parameter: Forced Expiratory Volume in one second / Forced Vital Capacity ratio: mean ± SD
Time frame: Baseline and 6 months (±2)
Change of Forced Expiratory Flow at 25-75% of forced vital capacity via spirometry
Absolute value of the following parameter: Forced Expiratory Flow at 25-75% of forced vital capacity \[FEV25-75 (%), mean ± SD\]
Time frame: Baseline and 6 months (±2)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
* Overall summary of adverse drug reactions (ADRs) will be presented the number of subjects and percentage of subjects with any ADRs, including suspected ADRs and serious ADRs (e.g., nasopharyngitis, pneumonia, hypertension, headache, ischaemic heart disease, angina pectoris, myocardial infarction, myocardial ischaemia, coronary artery disease, respiratory tract infection viral, oral candidosis, muscle spasms, dry mouth, among others) * Overall summary of serious adverse events (SAE) will be presented the number of subjects and percentage of subjects with any SAE (e.g., nasopharyngitis, pneumonia, hypertension, headache, ischaemic heart disease, angina pectoris, myocardial infarction, myocardial ischaemia, coronary artery disease, respiratory tract infection viral, oral candidosis, muscle spasms, dry mouth, among others)
Time frame: 6 months (±2)
Descriptive statistics
Patient profile - Descriptive statistics of : 1. Demographic Data: Age; Sex; and State/region of residence. 2. Clinical characteristics * Smoking history * COPD characteristics * Relevant medical history * COPD treatment * Concomitant medications * Vital signs
Time frame: Baseline and 6 months (±2)
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.
Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 14 months is below that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →